





December 26th 2022

Company name: FINDEX Inc

Name of representative: Teruo Aibara, President & CEO

(Securities code: 3649; PRIME

Market)

Inquiries: Atsushi Fujita, Director and Head

of Administration

(Telephone: +81-89-947-3388)

## **Notice of Revision of Medium-Term Business Plan**

At the ordinary meeting of the Board of Directors held on December 26<sup>th</sup> 2022, Findex Inc. decided to revise part of the strategies and target figures on its medium-term business plan "Vision for 2025", which was originally disclosed on July 5<sup>th</sup> 2021.

## 1. Factors for the Revision

The Company has formulated a five-year medium-term business plan covering the period from 2021 to 2025 and has been executing priority measures to achieve its corporate goals, and both sales and profits reached the all-time high in 2021. However, the prolonged outbreak of the covid-19 infection restricted many of our sales activities to medical institutions, and there was also a significant delay in the schedule for conformity qualification of medical device Regulation (MDR) in the EU region. The Company has decided to partially revise the plan due to the unavoidable impact of these events, as well as the need for proactive disclosure of non-financial information, such as our policies on sustainability and human capital initiatives.

In light of the uncertain outlook due to major changes in the external environment, the Company will reassess the plans for each business segment and revise them based on figures that are fairly achievable in the current situation. Its business has traditionally been in the public interest, such as supporting the digitization of medical institutions and the development of medical devices, and it has long been practicing a management that values human capital. Given these factors, the Company will not be making any major changes to the basic policies and strategies of the plan, and it will continue to aim for business expansion and the establishment of highly profitable business models in each of its business segments.

## 2. Schedule

The revised medium-term business plan will be disclosed together with the announcement of the full-year financial results for the fiscal year ending December 31st, 2022, which is scheduled in February 2023.

## 3. Others

At present, there are no changes to the full-year forecast for the fiscal year ending December 31st 2022, which was announced on February 9th 2022.

Note: This report is a translation of the press release of the Company prepared in accordance with the provisions set forth in the Securities and Exchange Law and its related accounting regulations. The original version of this press release is written in Japanese. In the event of any discrepancies in words, accounts, figures or the like between this press release and the original, the original Japanese version shall govern.